Singapore markets close in 5 hours 29 minutes

Ono Pharmaceutical Co., Ltd. (OPHLF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
13.980.00 (0.00%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.00
Open14.45
Bid13.16 x 42300
Ask15.50 x 40000
Day's range14.45 - 14.45
52-week range12.66 - 19.83
Volume321
Avg. volume1,513
Market cap6.709B
Beta (5Y monthly)0.18
PE ratio (TTM)8.28
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.52 (3.70%)
Ex-dividend date27 Sept 2024
1y target estN/A
  • Reuters

    Japan's Ono Pharma says $2.4 billion Deciphera purchase 'first step' for global expansion

    Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets. With this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines. Ono Pharma is best known globally for its blockbuster cancer drug Opdivo, which is sold in the U.S. by partner Bristol-Myers Squibb.

  • Reuters

    Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion

    Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets. With this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines. Ono Pharma is best known globally for its blockbuster cancer drug Opdivo, which is sold in the U.S. by partner Bristol-Myers Squibb.

  • Reuters

    UPDATE 2-Japan's Ono to buy US drugmaker Deciphera for $2.4 bln

    Deciphera Pharmaceuticals said on Monday Japan's Ono Pharmaceutical Co will acquire the cancer drugmaker for $2.4 billion to expand its oncology portfolio and presence in the United States and Europe. Ono Pharma has offered $25.60 per share in cash, a premium of 74.7% to U.S.-based Deciphera's last closing price of $14.65. Some shareholders who own about 28% of Deciphera's outstanding stock have already agreed to tender their shares and support the deal, which is expected to close in the third quarter of 2024, the company said.